Aberdeen Group plc Has $47.80 Million Stock Holdings in Insulet Corporation $PODD

Aberdeen Group plc raised its position in Insulet Corporation (NASDAQ:PODD) by 8.1% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 154,822 shares of the medical instruments supplier’s stock after buying an additional 11,571 shares during the period. Aberdeen Group plc owned about 0.22% of Insulet worth $47,798,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. True Wealth Design LLC boosted its holdings in Insulet by 288.0% in the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 72 shares during the last quarter. Golden State Wealth Management LLC lifted its position in Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 69 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its stake in shares of Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 43 shares during the last quarter. Quent Capital LLC bought a new position in shares of Insulet in the 3rd quarter valued at about $49,000. Finally, Osterweis Capital Management Inc. acquired a new stake in shares of Insulet during the 2nd quarter worth approximately $51,000.

Insulet Stock Up 0.8%

Shares of Insulet stock opened at $242.74 on Monday. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88. The business has a 50-day moving average of $277.19 and a two-hundred day moving average of $306.43. The company has a market capitalization of $17.08 billion, a P/E ratio of 70.36, a price-to-earnings-growth ratio of 1.37 and a beta of 1.41. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Truist Financial reduced their price objective on shares of Insulet from $412.00 to $390.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Zacks Research downgraded Insulet from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a research report on Thursday, January 22nd. Wolfe Research upped their price objective on Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, UBS Group reissued a “buy” rating on shares of Insulet in a research note on Thursday, December 18th. Twenty investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $374.10.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.